Dr Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Dr Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss new treatment options for metastatic prostate cancer for ecancertv at ASCO GU 2016.

They discuss an open-label phase II study which evaluated the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases.

They also consider a new option arising for those CRPC patients who have become resistant to abiraterone and enzalutamide - the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

свернуть